Nanoform Finland Plc, a leading nanoparticle medicine performance-enhancing company, recently announced that key findings from two studies conducted in collaboration between Nanoform and Takeda were presented at the 15th American Drug Delivery & Formulation Summit (DDF) in Boston, USA.
The presentation entitled “Delivering Value for Patients Through Nanoforming in Plasma-Derived Therapies” will focus on two proof-of-concept studies conducted using Nanoform technology to enhance subcutaneous and inhaled biologic treatments.
The first study evaluated the suitability of nanoformed high-concentration biologics formulations for subcutaneous delivery. Protein concentrations above 200 mg/mL often exceed the acceptable viscosity limit for subcutaneous injection. The findings, supported by syringeability studies suggest that Nanoform’s patented biologics platform can achieve high protein concentrations in suspension formulations suitable for subcutaneous delivery.
The second non-clinical proof-of-concept study investigated nanoformed Alpha-1 antitrypsin (A1AT) in the treatment of Alpha-1 antitrypsin (AAT) deficiency, a genetic disorder linked to lung diseases such as emphysema. Results showed that the nanoformed therapy showed promise as a targeted therapeutic approach. AAT deficiency is typically treated with weekly intravenous (IV) infusions of plasma-derived AAT, which is often inconvenient for patients. The study evaluated dry powder inhalation as an alternative route of administration for AAT replacement therapy, leveraging Nanoform’s novel solidification platform.
About Nanoform
Nanoform is the medicine performance-enhancing company that leverages best-in-class innovative nanoparticle engineering technologies, expert formulation, and scalable GMP API manufacturing to enable superior medicines for patients. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services, from pre-formulation to commercial scale.
